Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) Shares Outstanding (Weighted Average) (2019 - 2024)

Benitec Biopharma (BNTC) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $37.3 million as the latest value for Q4 2024.

  • Quarterly Shares Outstanding (Weighted Average) rose 1346.03% to $37.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $37.3 million through Dec 2024, up 1346.03% year-over-year, with the annual reading at $34.3 million for FY2024, 1359.56% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $37.3 million in Q4 2024 for Benitec Biopharma, up from $27.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $42.1 million in Q3 2022 to a low of $6300.0 in Q2 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $10.4 million across 5 years, with a median of $2.3 million in 2023.
  • Biggest YoY gain for Shares Outstanding (Weighted Average) was 39199.87% in 2022; the steepest drop was 99.85% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $384679.0 in 2020, then plummeted by 72.16% to $107095.0 in 2021, then surged by 1413.87% to $1.6 million in 2022, then surged by 58.91% to $2.6 million in 2023, then skyrocketed by 1346.03% to $37.3 million in 2024.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BNTC at $37.3 million in Q4 2024, $27.9 million in Q3 2024, and $34.3 million in Q2 2024.